+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the XEN63 glaucoma gel stent implanted using two different surgical methods ab interno inside the eye and ab externo outside the eye. This study focuses on patients with glaucoma who have not responded well to medical treatments or conventional surgeries. The trial aims to compare outcomes such as adverse events and intraocular pressure control over 12 months. Participants will be randomly assigned to receive the XEN63 gel stent implanted via either the ab interno or ab externo approach on Day 1. About 130 adults aged 45 years or older with glaucoma will join this study. After implantation, participants will be followed for up to 12 months with regular hospital or clinic visits to monitor safety and effectiveness. During the study, participants will undergo medical assessments and eye exams to measure intraocular pressure and check for any adverse events. The main outcomes include the percentage of participants achieving a 20% or greater reduction in intraocular pressure on the same or fewer medications after 12 months. Secondary measures include changes in daily intraocular pressure and medication use. The study will be completed by November 2028.

Age: 45Years +All GendersPhase 3
29 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of NEXAGON4 lufepirsen ophthalmic gel in people with persistent corneal epithelial defects PCED, a condition where the corneal surface does not heal properly. This randomized, double-masked, vehicle-controlled study aims to understand how well NEXAGON works in treating PCED and its durability after treatment. This Phase 2 trial is sponsored by Glaukos Corporation and is conducted at multiple centers. Participants will be randomly assigned to receive one of three treatments applied topically to the eye once a week for 4 to 8 weeks a high dose of lufepirsen, a low dose of lufepirsen available only at EU sites, or a vehicle gel without the active drug. After the treatment period, a 4-week follow-up will monitor the condition. If the corneal defect does not heal or the healing is not maintained for 28 days, participants may enter an open-label treatment phase with NEXAGON for an additional 8 weeks. During the study, participants will undergo screening to confirm eligibility, receive weekly treatment applications, and be monitored for safety and healing progress. Researchers will assess corneal re-epithelialization and its durability as the main outcome. The total study participation includes the screening, up to 8 weeks of treatment, 4 weeks of follow-up, and possibly an 8-week open-label extension. Safety, efficacy, and healing durability will be closely observed throughout these periods.

Age: 2Years +All GendersPhase 2
28 locations
E

Actively Recruiting

This research aims to evaluate the rate of malposition and related clinical outcomes of the Hydrus Microstent implant in patients with primary open-angle glaucoma undergoing cataract surgery. The study focuses on patients with age-related cataracts and glaucoma managed with up to four topical medications, assessing device placement and safety over a 24-month period after surgery. Participants will undergo cataract surgery with placement of a monofocal intraocular lens followed immediately by implantation of the Hydrus Microstent device. The Hydrus Microstent is a crescent-shaped implant designed to create a pathway for fluid drainage in the eye. The study is a single-group, non-randomized clinical trial where all participants receive this combined treatment. During the study, participants will attend a screening visit, the surgery day, and eight post-operative visits scheduled from Day 1 through Month 24 to monitor device position and associated clinical effects. Researchers will track adverse events during surgery and post-operation and measure the rate of significant device malposition linked to clinical outcomes. The study is sponsored by Alcon Research and lasts up to 24 months post-surgery.

Age: 45Years +All GendersPhase Not Applicable
22 locations